ArticleRare tumors2010
Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate.
Article in Rare tumors, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Prostatic Adenosquamous Carcinoma With a Minute Squamous Component in the Initial Biopsy and Early Liver Metastasis: A Case Report.IJU case reports · 2026Article
- The diagnostic dilemma of squamous differentiation in prostate cancer: A case report.Urology case reports · 2025Article
- Primary Adenosquamous Carcinoma of the Prostate.Diagnostics (Basel, Switzerland) · 2024Article
- Adenosquamous carcinoma of the prostate with low PSMA expression.International urology and nephrology · 2023Article
- Intra-oral Acantholytic Squamous Cell Carcinoma: 55 Cases. Is this Variant more Aggressive?Head and neck pathology · 2022Article
- Adenosquamous Carcinoma of Skene's Gland: A Case Report and Literature Review.Frontiers in oncology · 2022Article
- Primary Adenosquamous Carcinoma of the Prostate with Rectal Invasion.Case reports in urology · 2022Article
- Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report.BMC medical genomics · 2021Article
- A population-based analysis of adenosquamous carcinoma of the salivary gland.Gland surgery · 2021Article
- Prostate squamous cell carcinoma developing 11 years after external radiotherapy for prostate adenocarcinoma.IJU case reports · 2020Article
- Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy.Urology case reports · 2020Article
- Adenosquamous carcinoma of the bile duct: a population-based study.Cancer management and research · 2018Article
- Adenosquamous carcinoma of the ampulla of Vater: a case report and literature review.World journal of surgical oncology · 2015Review
- Primary adenosquamous carcinoma of the esophagus.World journal of gastroenterology · 2013Article
- The contemporary management of prostate cancer.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to examine the epidemiology, natural history, treatment and long-term survival of patients with adenosquamous cell carcinoma of the prostate. The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify ASCC of prostate cases between January 1973 and December 2006. Survival probabilities were estimated using the Kaplan-Meier methods and compared using the log-rank test. A total of 25 patients with adenosquamous cell carcinoma of the prostate were identified during the study period. The median age was 74 years (range 53-98). Twenty percent of study subjects presented with metastatic disease. Among those patients with known grade (n=16), 75% had poorly or undifferentiated histology. A total of 40% of study subjects received radical prostatectomy, while 24% of the patients had primary radiation therapy. The 1-, 3-, and 5-year cancer specific survival rates for the entire cohort were 55.2%, 37.8%, and 30.3%, respectively. For patients who underwent prostatectomy, the 1-, 3-, and 5-year survival rates were 78%, 78%, and 63%, respectively. For the patients who did not receive prostatectomy, the 1-year survival rates were 38.7% and none survived to three years. Adenosquamous cell carcinoma is a rare aggressive subtype of prostate cancer with poor cancer specific survival. The development of new therapeutic approaches for this aggressive tumor is urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.